AZN spikes 6% after report it denies AstraZeneca-BMS merger talks

Investing.com - AstraZeneca shares surged approximately 6% on Wednesday after a senior source told Reuters there are "no discussions" between AstraZeneca and Bristol Myers Squibb over a potential deal, flatly quashing reports of a merger that would have created a pharmaceutical giant worth nearly $400 billion.

AstraZeneca (NASDAQ: AZN) and Bristol Myers Squibb (NYSE: BMY) are the two directly affected public companies; AZN bears the most immediate price risk given it absorbed a roughly 9% single-day selloff on Monday when the merger speculation first emerged, while BMY shareholders were widely viewed as the primary beneficiaries of any combination.

"There is no deal between AstraZeneca and BMS. There never was a deal to be done, and there are no discussions between the companies," the source told Reuters on Wednesday, speaking on condition of anonymity. Wednesday’s rebound partially reverses what had been AZN’s biggest one-day drop since 2020, triggered by reports published on Sunday, August 3 by the Financial Times. Reuters subsequently reported, citing a separate person familiar with the situation, that preliminary discussions had taken place, but said it was unable to determine at the time whether those discussions remained ongoing.

The scale of the mooted transaction had already strained credulity across the investment community. AstraZeneca, with a market capitalisation of roughly $264 billion, and BMS, at roughly $133 billion, would have formed a combined entity surpassing the $99.6 billion BMS-Celgene deal of 2019, previously the largest M&A transaction in pharmaceutical history. Yet analysts found the strategic logic thin. Jefferies, in a note cited by CNBC, described the idea as "more than a head scratcher," adding: "if there is one company that doesn’t need financial engineering, it’s AZ." Union Investment portfolio manager Markus Manns, speaking to Reuters, said the combination "does not make strategic or financial sense" and compared it to "the pharmaceutical industry’s equivalent of the FIFA privatisation moment."

AstraZeneca shareholders were particularly cool on the idea. Lucy Coutts, investment director at JM Finn, told Reuters that "the only advantage for AstraZeneca in this rumoured combination with BMS seems to be to accelerate its U.S. footprint and sales" and that "BMS shareholders would be the winners of any combination with AZN." The asymmetry was visible in market pricing: while AZN slid roughly 9% in London on Monday, making it the FTSE 100’s second-biggest decliner that session, BMY shares rose roughly 6% in premarket trading on the same day.

Antitrust exposure added another layer of scepticism. Both companies compete head-to-head in PD-(L)1 cancer immunotherapy, with BMS marketing Opdivo and AstraZeneca selling Imfinzi. They also hold the only two commercial anti-CTLA-4 agents on the market. Antitrust lawyer Andre Barlow of DBM Law Group, cited by FiercePharma, warned that significant regulatory divestitures would likely be required, complicating any path to deal completion.

The irony is that AstraZeneca’s organic growth story arguably made the merger unnecessary in the first place. The company beat second-quarter 2026 earnings estimates with EPS of $2.63 against a $2.48 consensus, and is pursuing an ambitious target of $80 billion in annual revenue by 2030. It completed a direct listing on the New York Stock Exchange in June 2026 and has committed $50 billion to U.S. research, development, and manufacturing investment by the same year. Analysts noted those commitments suggest a credible path to building U.S. scale without the regulatory and integration risks a mega-merger would entail.

With NYSE markets set to open Wednesday morning, U.S. investors will have their first opportunity to price the denial in regular trading. The session will test whether AZN’s London rebound holds across the Atlantic and whether BMY gives back some of Monday’s deal-premium gains. Volume in both names is likely to be elevated as the market re-assesses two stocks that spent most of the week repricing a deal that, according to those close to the matter, was never really on the table.

You May Also Be Interested In

• KeyBanc Upgrades Acadia Realty Trust (AKR) to Overweight
• RBC Capital Downgrades Hermes International (RMS:FP) (HESAY) to Sector Perform
• BofA Securities Downgrades Autohome Inc. (ATHM) to Underperform